NeuroVive Pharmaceutical AB and BridgeBio Pharma jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015
Original Article: NeuroVive out─licenses targeted LHON therapy to BridgeBio Pharma